Candel Therapeutics, Inc. (CADL)
| Market Cap | 284.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -52.20M |
| Shares Out | 32.48M |
| EPS (ttm) | -1.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,817,885 |
| Open | 9.14 |
| Previous Close | 9.96 |
| Day's Range | 8.25 - 10.00 |
| 52-Week Range | 1.08 - 14.60 |
| Beta | -0.94 |
| Analysts | Strong Buy |
| Price Target | 19.00 (+117.14%) |
| Earnings Date | Nov 14, 2024 |
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CADL stock is "Strong Buy" and the 12-month stock price forecast is $19.0.
News
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday.
Candel Therapeutics Announces Pricing of Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Candel Therapeutics Announces $80 Million Proposed Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunother...
Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight
Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in c...
Candel Therapeutics Stock Surges Over 100% - Here's Why
On Wednesday, Candel Therapeutics, Inc. CADL announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients.
Candel Therapeutics' cancer drug meets late-stage trial goals
Candel Therapeutics said on Wednesday its experimental prostate cancer drug met the main goal of a late-stage trial, sending the company's shares up 64% in premarket trading.
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic...
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
NEEDHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic...
Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think
Candel Therapeutics is working on intratumoral oncolytic virus therapy. A pair of mid to late-stage trials in prostate cancer are expected to read out in Q4. Positive findings could be the position of...
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic...
3 Biotech Names With Potential Catalysts By Year End
The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should con...
Candel Therapeutics to Join Russell 3000® Index
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic...
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
NEEDHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica...
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
NEEDHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica...
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica...
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC Management and scientific/medical thought leaders to discuss...
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica...
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
NEEDHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Candel Therapeutics, Inc. released positive interim results from the phase 2 study using CAN-2409 for treatment of patients with pancreatic ductal adenocarcinoma; Patients that took the drug with SOC ...
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
NEEDHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
NEEDHAM, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...
Candel Therapeutics stock jumps as pancreatic cancer treatment shows promise
Shares of Candel Therapeutics Inc. CADL, +280.95% climbed 15% early Friday after the company released new data from a trial of its experimental cancer treatment.
Candel Therapeutics stock soars 30%: find out more
Candel Therapeutics Inc is up roughly 30% in premarket on Friday after reporting positive interim data for its experimental treatment of non-metastatic pancreatic cancer. CAN-2409 data sends Candel Th...
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
NEEDHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi...